Randomized, open-label, multicenter study of azithromycin compared with doxycycline for treating anorectal Chlamydia trachomatis infection concomitant to a vaginal infection (CHLAZIDOXY study)

Olivia Peuchant, Edouard Lhomme, Marion Krêt, Bellabes Ghezzoul, Caroline Roussillon, Cécile Bébéar, Frédéric Perry, Bertille de Barbeyrac, and the Chlazidoxy study group, Olivia Peuchant, Edouard Lhomme, Marion Krêt, Bellabes Ghezzoul, Caroline Roussillon, Cécile Bébéar, Frédéric Perry, Bertille de Barbeyrac, and the Chlazidoxy study group

Abstract

Background: Chlamydia trachomatis can lead to a persistent infection in the lower gastrointestinal tract, suggesting a potential role of autoinoculation of cervical chlamydial infection from the rectal site, contributing to repeat infections. Moreover, around 75% of women with urogenital C. trachomatis have concurrent anorectal infection. Current treatment guidelines for urogenital C. trachomatis infection recommend either a single 1 g dose of azithromycin or doxycycline 100 mg twice daily for 7 days. Doxycycline appears to be more effective in treating anorectal infections as suggested in a population of men who have sex with men, but no randomized controlled trial (RCT) had directly compared azithromycin with doxycycline for the treatment of rectal infections. We propose an open-label RCT to compare the microbial cure obtained with a single 1 g dose of azithromycin versus 100 mg of doxycycline twice daily for 7 days, for the treatment of anorectal C. trachomatis infection concurrent to urogenital infection in women.

Methods and study design: A total of 460 women with C. trachomatis urogenital infection will be enrolled in the study. Women will be asked to provide self-collected anorectal swabs and will be randomized to receive either a 1 g single dose of azithromycin or doxycycline 100 mg twice daily for 7 days. Clinical and biological data will be collected and patients will complete questionnaires about their sexual behavior. The primary outcome is the microbial cure rate, defined as a C. trachomatis negative nucleic acid amplification test (NAAT) result in the anorectal specimens 6 weeks after treatment initiation among women with a C. trachomatis positive urogenital and anorectal NAAT result at the baseline. The secondary outcome is autoinoculation from the rectum to the vagina, which will be evaluated based on the number of women with the same C. trachomatis genotype profile that will be identified in an anorectal-positive specimen obtained 6 weeks after treatment initiation and in a vaginal-positive specimen obtained four months after treatment.

Discussion: The results of this trial will establish which treatment is more efficacious against anorectal infection and could affect recommendations for the treatment of urogenital C. trachomatis infection, taking into account concurrent anorectal infection.

Trial registration numbers: EudraCT number: 2017-002595-15. CLINICALTRIALS.

Gov identifier: NCT03532464. Date of registration: May 31, 2018.

World health organisation international clinical trials registry: NTC03532464. Secondary ID: CHUBX 2016/26. Date of registration: May 09, 2018.

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Design of the Chlazidoxy study.

References

    1. Goulet V, de Barbeyrac B, Raherison S, et al. Prevalence of Chlamydia trachomatis: results from the first national population-based survey in France. Sex Transm Infect 2010;86:263–70.
    1. Kersaudy-Rahib D, Lydie N, Leroy C, et al. Chlamyweb Study II: a randomised controlled trial (RCT) of an online offer of home-based Chlamydia trachomatis sampling in France. Sex Transm Infect 2017;93:188–95.
    1. Peuchant O, de Diego S, Le Roy C, et al. Comparison of three real-time PCR assays for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in young pregnant women. Diagn Microbiol Infect Dis 2015;83:335–7.
    1. Toyer AL, Trignol-Viguier N, Mereghetti L, et al. Interest of simultaneous Chlamydia trachomatis and Neisseria gonorrhoeae screening at the time of preabortion consultation. Contraception 2012;86:572–6.
    1. Lanjouw E, Ouburg S, de Vries HJ, et al. 2015 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS 2016;27:333–48.
    1. Andersson N, Boman J, Nylander E. Rectal chlamydia: should screening be recommended in women? Int J STD AIDS 2017;28:476–9.
    1. Chandra NL, Broad C, Folkard K, et al. Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal intercourse: a systematic review and meta-analysis. Sex Transm Infect 2018;94:320–6.
    1. Ding A, Challenor R. Rectal chlamydia in heterosexual women: more questions than answers. Int J STD AIDS 2014;25:587–92.
    1. Gratrix J, Singh AE, Bergman J, et al. Evidence for increased chlamydia case finding after the introduction of rectal screening among women attending 2 Canadian sexually transmitted infection clinics. Clin Infect Dis 2015;60:398–404.
    1. van Liere G, Dukers-Muijrers N, Levels L, et al. High proportion of anorectal Chlamydia trachomatis and Neisseria gonorrhoeae after routine universal urogenital and anorectal screening in women visiting the sexually transmitted infection clinic. Clin Infect Dis 2017;64:1705–10. 15.
    1. van Liere GA, Hoebe CJ, Wolffs PF, et al. High co-occurrence of anorectal chlamydia with urogenital chlamydia in women visiting an STI clinic revealed by routine universal testing in an observational study; a recommendation towards a better anorectal chlamydia control in women. BMC Infect Dis 2014;14:274.
    1. Peters RP, Nijsten N, Mutsaers J, et al. Screening of oropharynx and anorectum increases prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in female STD clinic visitors. Sex Trans Dis 2011;38:783–7.
    1. Sethupathi M, Blackwell A, Davies H. Rectal Chlamydia trachomatis infection in women. Is it overlooked? Int J STD AIDS 2010;21:93–5.
    1. Bavoil PM, Marques PX, Brotman R, et al. Does active oral sex contribute to female infertility? J Infect Dis 2017;216:932–5.
    1. Rank RG, Yeruva L. Hidden in plain sight: chlamydial gastrointestinal infection and its relevance to persistence in human genital infection. Infec Immun 2014;82:1362–71.
    1. Haute Autorité de Santé. Urétrites et cervicites non compliquées: stratégie diagnostique et thérapeutique de prise en charge 2015.
    1. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015;64:1–37.
    1. Kong FY, Tabrizi SN, Law M, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 2014;59:193–205.
    1. Taylor BD, Haggerty CL. Management of Chlamydia trachomatis genital tract infection: screening and treatment challenges. Infect Drug Resist 2011;4:19–29.
    1. Kong FY, Tabrizi SN, Fairley CK, et al. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. J Antimicrob Chemother 2015;70:1290–7.
    1. Bébéar C, de Barbeyrac B. Genital Chlamydia trachomatis infections. Clin Microbiol Infect 2009;15:4–10.
    1. Haute Autorité de Santé. Méthodes contraceptives: focus sur les méthodes les plus efficaces disponibles. 2013.
    1. Rodriguez P, de Barbeyrac B, Persson K, et al. Evaluation of molecular typing for epidemiological study of Chlamydia trachomatis genital infections. J Clin Microbiol 1993;31:2238–40.
    1. Peuchant O, Le Roy C, Herrmann B, et al. MLVA subtyping of genovar E Chlamydia trachomatis individualizes the Swedish variant and anorectal isolates from men who have sex with men. PLoS One 2012;7:e31538.
    1. World Health Organization. Guidelines for the Management of Sexually Transmitted Infections. Geneva: WHO; 2003.
    1. Kong FY, Hocking JS. Treatment challenges for urogenital and anorectal Chlamydia trachomatis. BMC Infect Dis 2015;15:293.
    1. O’Farrell N. Control of gonorrhoea and chlamydia in the UK. Lancet 2016;388:342.
    1. Horner PJ, Blee K, Falk L, et al. 2016 European guideline on the management of non-gonococcal urethritis. Int J STD AIDS 2016;27:928–37.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren